#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thrombotic thrombocytopenic purpura Hereditary hypophosphataemic rickets Follicular lymphoma stage II Medullary thyroid cancer Fibrosarcoma Transitional cell cancer of the renal pelvis and ureter Extra-osseous Ewing's sarcoma recurrent Dementia Alzheimer's type Undifferentiated sarcoma Malignant peritoneal neoplasm Glioblastoma multiforme Von Willebrand's disease Subarachnoid haemorrhage Advanced systemic mastocytosis Rhabdoid tumour More trials…

    Learn about Rare Diseases

    Hyperoxaluria – Treatment Kearns-Sayre syndrome – Basic Information Pleural mesothelioma malignant Mantle cell lymphoma refractory – Treatment Progressive supranuclear palsy – Diagnostics Chondrosarcoma Rhabdomyosarcoma – Life with Disease Marginal zone lymphoma refractory – Treatment CADASIL Adrenogenital syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Amisulpride HUPERZINE A Crisantaspase Lecanemab Dolutegravir Sodium Amiloride ALE.P02 Sabestomig Potassium Oxybate Tramazoline Hydrochloride Tng462 Soft Paraffin And Fat Products ARFOLITIXORIN Valaciclovir Artemisia Vulgaris (312) MORPHINE Mexiletine Art6043 Idarubicin Litenimod Sodium More therapies…

    Learn about Your Condition

    Cleft lip and palate Chronic hepatic failure Brain neoplasm Large cell lung cancer stage 0 Lymphangiosarcoma C3 glomerulopathy Cardiomyopathy Pre-eclampsia Somatic symptom disorder Postpartum haemorrhage Pyelonephritis acute Hip fracture Thyroidectomy Vulvar dysplasia Dermatitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatitis atopic

  • Study on Long-Term Safety of GSK1070806 for Patients with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Humanised Igg1 Kappa Monoclonal Antibody Against Interleukin 18
    Bulgaria Czechia France Germany Greece Italy +2

  • Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Upadacitinib
    Belgium Bulgaria Germany Hungary Italy The Netherlands +4

  • Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Fluocinolone Acetonide
    • Triamcinolone
    • Pimecrolimus
    Austria Belgium Bulgaria Croatia Czechia Finland +12

  • Study on the Effects of LEO 138559 for Adults with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Humanised Igg1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha
    Czechia France Germany Hungary Poland Romania +1

  • Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Germany The Netherlands

  • Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

    Not recruiting

    3 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Upadacitinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +9
Previous Page
1 … 10 11 12 13 14 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!